Welcome to Chiesi
USA
Home page > News
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
05-06-2025
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability
16-04-2025
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth
29-01-2025
Chiesi USA Releases 2023 Sustainability Report and Highlights US Community Engagement Strategy Focus Areas
09-10-2024
Chiesi to Present New Data Showcasing Depth of Respiratory Leadership at the American Thoracic Society 2024 International Conference
16-05-2024
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
22-04-2024
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
15-04-2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
05-03-2024
Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023
08-08-2023
Chiesi USA CEO Appointed to ASHP Foundation Board of Directors
20-07-2023
Chiesi USA Partners with Smith Anderson to Host 1L Excellence in Diversity Fellow this Summer
12-06-2023
2022 for Chiesi: The Group’s international growth continues
11-04-2023
Chiesi USA donates more than $830,000 to local communities and nonprofits in 2022
28-03-2023
Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention
02-12-2022
Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome
29-11-2022
Chiesi Group joins Biden Administration pledge to decarbonize health care sector, make facilities resilient to climate change
10-11-2022
Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals
17-10-2022
Chiesi USA Partners with Durham Bulls to Donate $15,000 to Three Triangle Nonprofits
03-10-2022
Chiesi is Recertified as a B Corp and Sets New Tougher Objectives for Action by 2025
22-09-2022
Chiesi USA Reports Progress in ASHP Foundation’s Pharmacy Leadership Scholars Program
06-09-2022
Chiesi Group joins White House pledge to decarbonize healthcare sector
25-07-2022
Chiesi tracks actions taken for a healthier, more sustainable future
14-07-2022
Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice
01-06-2022
Chiesi Group Continues to Grow In 2021
11-04-2022
Chiesi USA donates more than $815,000 to local communities and nonprofits in 2021
16-03-2022
Chiesi USA certified as a Great Place to Work® in 2021
24-02-2022
Chiesi USA Announces New Publication of Post Hoc Analysis on Timing of Ischemic Events in Cardiac Patients and Role of KENGREAL® (cangrelor) in Reducing Risk
25-01-2022
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2022
24-01-2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
20-12-2021
Chiesi Global Rare Diseases Announces Updated U.S. Prescribing Information for FERRIPROX® (deferiprone)
03-12-2021
Chiesi USA Promotes Polly Petrino to VP, Finance and Member of Leadership Team
08-11-2021
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the Treatment of Iron Overload in Sickle Cell Disease
15-10-2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease
15-10-2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease
14-10-2021
Chiesi USA Donates nearly $15,000 to Three Triangle Nonprofits through Partnership with Durham Bulls
06-10-2021
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Brazil for the Treatment of Iron Overload in Sickle Cell Disease
13-09-2021
Chiesi USA Announces Publication of Cost-Consequence Analysis of KENGREAL® (cangrelor) in Cardiac Patients at High Risk of Complications Following PCI in the American Journal of Cardiovascular Drugs
10-08-2021
Chiesi accelerates path toward full sustainability despite COVID-19 pandemic
23-06-2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease Companies Announce Topline Results from Interim Analysis of Phase III BALANCE Clinical Trial
02-06-2021
Chiesi USA, Inc. Earns 2021 Life Sciences Award by Triangle Business Journal for second consecutive year
24-05-2021
Chiesi USA announces new organizational leadership for the Chiesi Foundation
13-05-2021
Chiesi Group calls for #ActionOverWords in the fight against climate change
10-05-2021
Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease
01-05-2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
28-04-2021
Chiesi USA Appoints VP of Medical Affairs to Support Continued Growth
29-03-2021
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
22-03-2021
Chiesi Group announces performance growth in 2020
18-03-2021
Chiesi USA, Inc. announces Commercial Availability of Bronchitol® (mannitol) inhalation powder for improvement in pulmonary function in adult patients with cystic fibrosis
17-03-2021
Chiesi USA Announces Sponsorship of ASHP Foundation’s Pharmacy Leadership Scholars Program
16-03-2021
Chiesi USA donates more than $800,000 in 2020
01-03-2021
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
26-02-2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
23-02-2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
10-02-2021
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2021
25-01-2021
Chiesi USA Announces Key Promotions to Business Unit Leads
21-01-2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
30-12-2020
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease
23-12-2020
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease
23-12-2020
Chiesi USA Appoints Jon Zwinski as General Manager and Chief Executive Officer
08-12-2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
27-11-2020
Chiesi USA, Inc. Supports March of Dimes Eastern North Carolina in Observance of Prematurity Awareness Month
17-11-2020
Chiesi USA, Inc. Earns Fourth Consecutive Corporate Philanthropy Award by Triangle Business Journal
11-11-2020
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
02-11-2020
Chiesi Global Rare Diseases Launches “Rethink Fabry” Campaign to Bring Important Information to Fabry Disease Community and Support Patients and Caregivers
13-10-2020
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
02-10-2020
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
17-09-2020
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the ProposedTreatment of Fabry Disease
25-08-2020
Chiesi USA, Inc. Earns 2020 Life Sciences Award by Triangle Business Journal
24-08-2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
11-08-2020
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
16-07-2020
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
10-07-2020
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
10-07-2020
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
30-06-2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
28-05-2020
Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day tablets
21-05-2020
Chiesi Global Rare Diseases Recognizes Fabry Disease Awareness Month and Launches “Fabry Focus on Health” Educational Series to Support Patients and Caregivers During COVID-19 Pandemic
24-04-2020
Chiesi USA increases support measures for employees, patients and community partners in response to COVID-19 pandemic
31-03-2020
